Targeted DMARDs in RA
A Closer Look at RA Treatment: Targeted DMARDs

Released: December 11, 2020

Expiration: December 10, 2021

Stanley B. Cohen
Stanley B. Cohen, MD
Sheetal Desai
Sheetal Desai, MD, MSEd
Eric M. Ruderman
Eric M. Ruderman, MD

Activity

Progress
1
Course Completed

In this episode, Dr. Stanley Cohen, Dr. Sheetal Desai, and Dr. Eric Ruderman discuss the recent changes in rheumatoid arthritis treatment options, reviewing the landscape of targeted DMARDs and JAK inhibitors, including:

  • Kinase signaling
  • JAK inhibitor activity and signaling
  • JAK selectivity

Presenters:

Stanley B. Cohen, MD
Clinical Professor 
Department of Internal Medicine
University of Texas Southwestern Medical School
Co-Director
Division of Rheumatology
Presbyterian Hospital
Co-Medical Director
Metroplex Clinical Research Center
Dallas, Texas 

Sheetal Desai, MD, MSEd
Chief of Rheumatology
Program Director
University of California, Irvine
Irvine, California

Eric M. Ruderman, MD
Professor, Associate Chief
Division of Rheumatology
Northwestern University Feinberg School of Medicine
Clinical Practice Director
Northwestern Medical Group
Chicago, Illinois